Status:

RECRUITING

Efficacy of Morphine in Reducing the Rate of Early Non-Invasive Ventilation Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Phase I/IIa

Lead Sponsor:

University Hospital, Grenoble

Conditions:

Chronic Obstructive Pulmonary Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

Acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are a major source of morbidity and mortality for patients and cost to the society. In case of acute respiratory failure with hyperc...

Detailed Description

Patients included in this dose-finding study will be enrolled consecutively after consent and verification of the selection criteria, with a minimum of 24 hours after completion of previous patient fo...

Eligibility Criteria

Inclusion

  • Patients Aged ≥ 18 years
  • Current or former smoker at least 10 packs-years
  • Patient with a history of COPD according to the Gold guidelines , after review of the medical record by the physician in charge
  • Acute exacerbation of COPD (greater degradation of respiratory symptoms than the usual daily variations and requiring a modification of therapeutic management)
  • Need to implement NIV treatment (respiratory acidosis with pH\<7.35)
  • Ventilation frequency \> 20min
  • Affiliation to the French security system (or equivalent)
  • Written informed consent from the patient or his surrogates. In patients who are not able to consent on admission an emergency inclusion procedure will be allowed, with a mandatory delayed consent.

Exclusion

  • Patient already treated by NIV during admission (e. g. introduction in pre-hospital by SMUR) or started more than one hour ago in the department.
  • Sedative (barbiturates, benzodiazepines and related substances and other sedatives) or morphine treatment within 24 hours before inclusion
  • Chronic alcoholism
  • Contra-indication to NIV: disturbances of consciousness (Glasgow \< 11) except moderate hypercapnic encephalopathy; indication of immediate intubation; risk of inhalation; sputum impossible; hemodynamic instability; inability to remove the mask; trauma, surgery or facial malformation; patients with pH \< 7.25 can only be included in intensive care unit or in the vital emergency room of the emergency department, under continuous monitoring
  • NIV with palliative purpose from the outset with death expected within 24 hours of inclusion
  • Non-communicative patient or significant dementia making them unable to participate in the study
  • Contra-indication to morphine without acute respiratory distress
  • Pregnant or breastfeeding women
  • Major mentioned in Articles L1121-6 and 1121-8 of French public health cod
  • Patients in a period of exclusion from other research involving the human person type 1 or 2
  • Subject cannot be contacted in case of emergency

Key Trial Info

Start Date :

December 8 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2027

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT04427826

Start Date

December 8 2020

End Date

January 1 2027

Last Update

November 29 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Emergency Department of Grenoble Alpes University Hospital

Grenoble, Isère, Auvergne-Rhône-Alpes, France, 38043